echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The number of Chinese enterprises in the top 500 exceeds that of the four pharmaceutical companies in the United States and surpasses BMS.

    The number of Chinese enterprises in the top 500 exceeds that of the four pharmaceutical companies in the United States and surpasses BMS.

    • Last Update: 2020-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The Fortune 500 is the most famous list of the world's largest companies and is known as the "ultimate list".
    the list, which is based on revenue, this year's total revenue reached $33 trillion, a record high and close to the combined GDP of China and the United States.
    threshold for entry to the rankings (minimum sales revenue) also rose from $24.8 billion to $25.4 billion.
    year's most eye-catching change was undoubtedly the historic leap forward for Chinese mainland: the number of Chinese mainland companies, including Hong Kong, reached 124, surpassing the US (121) for the first time in history.
    , plus companies in Taiwan, a total of 133 companies in China are on the list.
    , there are eight new companies on the list, namely Shanghai Construction, Shenzhen Investment Holdings, Shenghong, Shandong Iron and Steel, Shanghai Pharmaceuticals, Guangxi Investment, China's nuclear industry and China Coal Energy.
    Shanghai Pharmaceuticals as an outstanding representative of the pharmaceutical industry appeared on the list, since then, China Pharmaceutical Group is no longer alone.
    's ranking has also been moving forward, rising 24 places from last year to 145th place, ranking among top 150.
    Source: Fortune Chinese Network 01 pioneered the "black horse" of the top 500 three years ago, Shanghai Pharmaceutical Chairman Zhou Jun predicted to E drug managers: China's pharmaceutical industry will have a number of Fortune 500 enterprises born.
    shanghai Pharmaceuticals into a World 500 company within five years is one of the strategic goals set for the board by the Shanghai Pharmaceutical Executive Team.
    2020, two years before the target is reached, Shanghai Pharma has taken the lead in breaking through and realizing its dream of a global top 500.
    China is the world's second-largest pharmaceutical market, but it has been short of products and companies that match its market size, and for years, only one of the world's top 500 companies has held a "single seed".
    interview three years ago, Zhou Jun said that China's pharmaceutical industry leaders, through innovation, mergers and acquisitions, industrial integration and other ways, can achieve a bigger and stronger vision.
    In fact, most of the world's leading pharmaceutical companies are now expanding through mergers and acquisitions, such as BMS's involvement in the global pharmaceutical-scale TOP5 in 2019 through a merger with Xinji, and Takeda Pharmaceuticals' acquisition of Shire into TOP10.
    , Shanghai Pharma could follow the example of these well-known MNCs and enter the world's top 500 through mergers and acquisitions on behalf of Chinese pharmaceutical companies.
    What's more, Shanghai Pharma actually has a merger gene, in 2010, including Shanghai Pharmaceuticals, including the three "Shanghai Industrial Group" companies to "New Shanghai Pharmaceuticals" as the carrier to achieve the overall listing.
    2011, Shanghai Pharma was listed on the Hong Kong Stock Exchange, becoming the first mainland listed company to list "A-H" Pharmaceuticals, including a merger and acquisition of six companies, including Kantrys and Tianpu Biopharmaceuticals, in 2018.
    11 years, Shanghai Pharma through these foreign mergers and acquisitions and endo-growth, to achieve a business size of 7 times growth, net profit growth of 4 times, market value growth of 3 times, it can be said that step by step shanghai Pharma to the top 500 steps.
    , the next step is not mergers and acquisitions.
    recent years, Shanghai Pharmaceutical's innovation and transformation is gradually making efforts, whether it is the pharmaceutical business, or the pharmaceutical industry, are moving forward at different paces.
    Pharmaceutical business, the drug to seize the dividend of innovative drugs, expand the import of drug agents, in 2018 to obtain 15 new drugs, including K drugs, O drugs, such as the total import qualification, in 2019 continue to win including dacotinib tablets, Perserica monoanti, Aliciu mono-resistant and other 17 heavy-duty new drug species of the domestic exclusive agent.
    vaccine agency, The drug has become the only domestic vaccine import distributor outside of Zhifei bio, covering 31 provinces and counties of 2000 district and county CDC, market share estimated at about 10%.
    Pharmaceutical industry, shanghai medicine through "independent research and development and external introduction" two-wheel drive model to innovation transformation, on the one hand, increase research and development investment, last year with 1.35 billion yuan of research and development absolute value of domestic ahead, in addition to new product-related research and development personnel to carry out unique equity incentives;
    August 7th, Shanghai Pharmaceuticals plans to invest no more than 1.15 billion yuan to introduce T3011, a global innovative lysovirus product, to gain its exclusive interest in the development, production, registration and sale of the company in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan).
    same time, CDE issued a notice for public consultation on the Guidelines for the Design of Clinical Trials of Lysovirus-type Drugs (Draft for Comments), the first time in China and without precedent in Europe and the United States.
    fact, this is not the first time Shanghai Pharma has invested in lysovirus.
    , Shanghai Pharma acquired the world's first and only lysovirus product, Akori, through the acquisition of its controlling subsidiary, Shanghai 3D Bio.
    In recent years, Shanghai Pharma has continued to invest in Ankeri, and has been approved to cooperate with eight Sanjia hospitals in Shanghai to carry out clinical re-evaluation research work after the listing of Ankeri, actively expand new adaptive disorders, as well as joint therapies with PD-1 is also carrying out clinical research.
    the same time, Tamp Bio, which is owned by Shanghai Pharmaceuticals, has restarted Its re-listing plans.
    , Shanghai Pharmaceuticals believes that lysovirus products have broad prospects and co-use space, and may become the next PD-1 level of products.
    02 Shanghai Pharma is an unexpected surprise for the four new pharmaceutical companies that have entered this year, with Takeda (414th) and BMS (487th) all foreshadowing big acquisitions, including Takeda's acquisition of Shire and BMS's acquisition of Xinji.
    Somerset (498th), the most valuable company in the life sciences sector, is also dependent on industry acquisitions, large and small, and on March 3rd it pocketed QIAGEN revenue for $11.5bn, making it the second-largest acquisition in its history.
    In January 2019, Takeda announced the completion of its acquisition of "one brother" Shire in the rare disease pharmaceutical sector, adding rare diseases and blood products to Takeda's core areas, making it one of the world's top 10 pharmaceutical companies.
    On June 24, Takeda Pharmaceuticals released its annual report for fiscal 2020, with operating income of 3.29 trillion yen (about 216.2 billion yuan), up 56.93 percent year-on-year, and net profit attributable to common shareholders of the parent company of 44.241 billion yen, down 59.46 percent year-on-year.
    identity transformation is the first layer of "benefits" brought to Takeda by mergers and acquisitions, and the products are deeper benefits.
    2020, Takeda expects to list 5-7 new drugs in China and more than 15 innovative drugs in China in the next 3-5 years, said Shan Guohong, president of Takeda China.
    noteworthy is that four of the seven new drugs to be marketed in fiscal year 2020 are new drugs for rare diseases, and the current injection of Vidriju monoanti, vibutoxi monoantigen has been approved.
    the same is true of BMS, which reported global revenues of $20.91bn in the first half of 2020, up 71 per cent year-on-year, mainly due to the acquisition of New Base.
    In early 2019, BMS' largest acquisition in biopharmaceutical history, the $74 billion acquisition of New Base Pharmaceuticals, was followed by BMS's 11th-place finish in the TOP50 list of global pharmaceutical prescription drug sales by Pharmaceutical Managers of the United States, squeezing Johnson and Johnson into fifth place.
    from the current drug trends, BMS has a lot to offer: the company's pipeline is more focused, patent expired products less.
    2019, more than 90% of BMS products covered three areas, of which the tumor sector income contribution accounted for 50%, cardiovascular, autoimmune drugs accounted for 30%, 11%.
    , on the other hand, only 9% of BMS patent expired products contribute, better than most MNC, including Pfizer, Mercedon, etc.
    , BMS faces the biggest question after the merger is how to do a good job of integration after the acquisition.
    From the existing products, most of BMS products have not achieved the volume, large varieties like O drug growth is not good, as the first listed PD-1, 2019 sales of $7.2 billion, growth rate of only 7%, to the first half of this year, O drug began to decline, revenue of $3.419 billion, down 6% year-on-year.
    gap is widening compared to Mercadon's K-drug, with cumulative revenue of $6.672 billion in the first half of the year, up 38% year-on-year.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.